(19)
(11) EP 3 461 845 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
29.05.2019 Bulletin 2019/22

(43) Date of publication:
03.04.2019 Bulletin 2019/14

(21) Application number: 18203676.4

(22) Date of filing: 12.12.2014
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61P 35/02(2006.01)
A61K 39/395(2006.01)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 13.12.2013 US 201361916087 P

(62) Application number of the earlier application in accordance with Art. 76 EPC:
14824269.6 / 3080164

(71) Applicant: Genentech, Inc.
South San Francisco, CA 94080 (US)

(72) Inventors:
  • Yu, Shang-Fan
    South San Francisco, CA 94080 (US)
  • Liang, Wei -Ching
    South San Francisco, CA 94080 (US)
  • Wu, Yan
    South San Francisco, CA 94080 (US)
  • Leong, Steven
    South San Francisco, CA 94080 (US)
  • Polson, Andrew
    South San Francisco, CA 94080 (US)

(74) Representative: Mewburn Ellis LLP 
City Tower 40 Basinghall Street
London EC2V 5DE
London EC2V 5DE (GB)

 
Remarks:
This application was filed on 31-10-2018 as a divisional application to the application mentioned under INID code 62.
 


(54) ANTI-CD33 ANTIBODIES AND IMMUNOCONJUGATES


(57) The disclosure provides anti-CD33 antibodies and immunoconjugates and methods of using the same.